PA
SCMP

Parallel Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Parallel Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-2,000
Closed -$27K – 2143
2016
Q4 		$27K Buy
+2,000
New +$27.9K 0.01% 766

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's SCMP Position: Q1 2017 in Review

Parallel Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 2,000 shares — an estimated $27K sold.

Parallel Advisors first reported a position in SCMP in Q4 2016 and held it in 1 quarter. The position peaked at $27K in Q4 2016. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • Parallel Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Parallel Advisors sold 2,000 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $27K.
  • Parallel Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Parallel Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $27K in Q4 2016.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Parallel Advisors's 13F filing for Q1 2017, filed 12 May 2017.